BofA upgrades Schott Pharma stock to Neutral at EUR 27.00

Published on 10/29/2026 at 12:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue rose 9.87 percent to EUR 281.76 million. Schott Pharma stock costs EUR 25.25 on October 29, 2026, matching the EUR 25.25 Xetra close.

Analyst views and upcoming dates

BofA set a EUR 27.00 target on October 16, 2026.
Third-quarter revenue reached EUR 281.76 million, up 9.87 percent year over year.
Schott Pharma stock trades at EUR 25.25 at 12:42 p.m. CEST at Lang & Schwarz on October 29, 2026, unchanged versus the Xetra close of October 28, 2026.
SCHOTT Pharma will attend the BNP Midcap CEO Conference on November 17, 2026.

Schott Pharma, DE000A3ENQ51, Illustration mit AI erstellt.

SCHOTT Pharma (ISIN DE000A3ENQ51) was trading at EUR 25.25 at Lang & Schwarz on October 29, 2026, unchanged versus the Xetra close of October 28, 2026 at EUR 25.25. The latest analyst signal came from BofA, which upgraded the stock from Underperform to Neutral and set a EUR 27.00 price target on October 16, 2026, according to Markets Insider.

Revenue gives the rating context

Schott Pharma's third-quarter revenue reached EUR 281.76 million, an increase of 9.87 percent from the year-earlier period. The company also reported an adjusted EBITDA margin of 26.80 percent for the quarter, according to Investing.com. That combination puts the focus on profitable growth rather than revenue expansion alone.

Three analyst signals since September

On September 15, 2026, JPMorgan initiated coverage with an Overweight rating and a EUR 27.10 target. On October 9, 2026, Deutsche Bank cut its rating from Buy to Hold but raised its target from EUR 23.00 to EUR 25.00, as reported by MarketScreener. BofA then moved from Underperform to Neutral on October 16, 2026, with its EUR 27.00 target.

What dates matter next?

SCHOTT Pharma is scheduled to attend the BNP Midcap CEO Conference on November 17, 2026, according to its SCHOTT Pharma investor-relations page. MarketScreener lists the annual 2026 earnings release for December 9, 2026, giving investors a clear next reporting milestone.

Price holds the Xetra line

The unchanged euro quote leaves the share below BofA's EUR 27.00 target by EUR 1.75, while the latest revenue increase provides a measurable operating counterpoint to valuation concerns. The Xetra listing is in the Prime Standard and the company operates in medical equipment, supplies and distribution.

Schott Pharma was trading at EUR 25.25 at Lang & Schwarz on October 29, 2026 at 12:42 p.m. CEST, unchanged versus the Xetra close of October 28, 2026 at EUR 25.25. The further course of trading is shown by the continuously updated real-time quote of Schott Pharma stock.